ISIvan Solarte

Ivan Solarte

*This is an algorithmically generated author record based on publicly available information.

Ivan Solarte has a total of 163 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association of Easier Biologic Access with Remission and Other Clinical Outcomes in Severe Asthma: A Global Real-World Study

    by Susanne Hansen, Ming-Ju Tsai, Trung N Tran, John D Blakey, Benjamin Emmanuel, Shawn D Aaron, Yahya Habis, Valeria Perugini, Alan Altraja, Rohit K Katial, et al.

    Purpose: Time to biologic initiation for the treatment of severe asthma (SA) is affected by many factors, including ease of access to biologics, which is often subject to approval by regulatory authorities and reimbursement criteria by relevant agencies. We investigated the association between ease of biologic access (using the biologic accessibility score [BACS] as a proxy) and post-biologic asthma outcomes, including remission. Methods: This ecological study, using data from CHRONICLE (a US severe asthma registry), the International Severe Asthma Registry (ISAR), and the Optimum Patient Care Research Database (OPCRD), included patients with SA from 21 countries. Associations at the country level, between BACS, a composite score of prescription criteria for biologics in SA, and the proportion of patients with a favorable asthma outcome 1-year post-biologic in each setting (ie ISAR country or in the CHRONICLE or OPCRD datasets) were tested. Several definitions of favorable outcome were used, including proportion of patients who achieved clinical remission (defined using 2, 3 and 4 domains), experienced no exacerbations, had well- or partly controlled asthma, a percent predicted forced expiratory volume in 1 second (ppFEV1) or percent predicted peak expiratory flow rate (ppPEFR) ≥ 80%, and no long-term oral corticosteroid (LTOCS) use. Results: A total of 9,183 patients were included. A higher BACS (as a proxy of easier access to biologics) was associated with a higher likelihood of achieving clinical remission (p≤ 0.001), no exacerbations (p< 0.001), well- or partly controlled asthma (p=0.047), a ppFEV1 or ppPEFR ≥ 80% (p=0.004), and no need for LTOCS (p=0.045) 1 year post-biologic initiation. Conclusion: Easier access to biologics for patients with SA, a prerequisite for shorter time-to-initiation, was associated with a greater probability of achieving clinical remission and other favorable asthma outcomes. Initiating biologics earlier in the asthma disease course may help unlock greater therapeutic potential in SA. These findings warrant confirmation in additional studies to further establish the causal relationship between biologic accessibility, timing of initiation, and clinical outcomes in SA.

  • Attitudes, barriers, and facilitators for the use of rescue therapy in patients with mild to moderate asthma

    by Olga Milena García Morales, Carlos Andrés Celis-Preciado, Iván Solarte, Juliana Velosa-Porras

    To explore and understand the barriers and facilitators for correctly using maintenance/controller and rescue treatments in adults with mild to moderate asthma (GINA 2020 classification) attending a reference center for asthma in Bogotá, Colombia, during the years 2021-2022. A qualitative study with a phenomenological approach using semi-structured interviews with adults with mild to moderate asthma, under a purposive non-probabilistic sampling. Data analysis was conducted using Nvivo software (Version 11.0) through: reading and re-reading, memo generation, coding, category generation, and connection between categories. Thirty-one patients were interviewed (mean age: 44.3 years) with a 1:1 male/female ratio. 77.4% with moderate asthma. Patients' experiences were grouped into three themes with 12 categories: barriers related to the individual (inadequate knowledge about maintenance inhalers, insufficient understanding of their current state due to lack of information, disagreement in treatment among non-adherent patients, and difficulties in implementation and practical application), barriers related to the healthcare system (lack of follow-up, medication availability, administrative procedures, and waiting times), and patient-related facilitators (adequate knowledge of the functioning and correct use of inhalers for treatment, proactive attitude, and motivation to receive information). Based on the identified barriers, educating patients about the pathophysiological mechanisms of asthma (inflammation and bronchodilation) and the concept of control adapted to the patient's language could facilitate the appropriate and adherent use of pharmacological therapy.

  • Open Access

    Fibrosis pulmonar en infección por SARSCoV- 2: ¿qué sabemos hasta ahora? ¿Qué podemos esperar?

    by July Vianneth Vianneth Torres González, Juan David Botero Bahamon, Carlos Andrés Celis Preciado, María José Fernández Sánchez, Claudio Villaquirán Torres, Olga Milena García Morales, Ivan Solarte Rodríguez, Patricia Hidalgo Martínez, Mary Bermudez

    La infección por SARS-CoV-2 le ha traído grandes retos al personal de salud durante 2020. Aprender sobre su comportamiento, fisiopatología, afectación pulmonar y su progresión a síndrome de dificultad respiratoria aguda (SDRA), además de las intervenciones farmacológicas y la mortalidad, han representado un desafío científico en los centros de atención especializada. No obstante, y a pesar de los avances sobre la infección aguda, poco se conoce respecto a las potenciales secuelas posteriores a la infección leve, moderada o severa por SARS-CoV-2, entre ellas la posible afectación fibrosante del parénquima pulmonar, que de acuerdo con la experiencia sobre infecciones por otros coronavirus (síndrome respiratorio agudo severo y síndrome respiratorio de Oriente Medio) y otras causas de SDRA, puede ser una de las complicaciones más severas y con mayor impacto en la calidad de vida y en la funcionalidad de las personas, una vez superada la infección. En este artículo se revisa la evidencia disponible sobre el desarrollo de la enfermedad pulmonar intersticial de tipo fibrosante asociada con la infección por SARS-CoV-2, los posibles mecanismos fisiopatológicos, los hallazgos imagenológicos y el plan de manejo propuesto hasta el momento, especialmente en términos de rehabilitación integral de estos pacientes.


  • Open Access

    Discrepancies between perceptions of students and deans regarding the consequences of restricting students’ use of electronic medical records on quality of medical education

    by Ivan Solarte, Karen D. Könings

    Electronic medical records (EMR) are more used in university hospitals, but the use of EMR by medical students at the workplace is still a challenge, because the conflict of interest between medical accountability for hospitals and quality of medical education programs for students. Therefore, this study investigates the use of EMR from the perspective of medical school deans and students, and determines their perceptions and concerns about consequences of restricted use of EMR by students on quality of education and patient care. We administered a large-scale survey about the existence of EMR, existing policies, students’ use for learning, and consequences on patient care to 42 deans and 789 Residency Physician Applicants in a private university in Colombia. Data from 26 deans and 442 former graduated students were compared with independent t tests and chi square tests. Only half of medical schools had learning programs and policies about the use of EMR by students. Deans did not realize that students have less access to EMR than to paper-based MR. Perceptions of non-curricular learning opportunities how to write in (E)MR were significantly different between deans and students. Limiting students use of EMR has negative consequences on medical education, according to both deans and students, while deans worried significantly more about impact on patient care than students. Billing issues and liability aspects were their major concerns. There is a need for a clear policy and educational program on the use of EMR by students. Discrepancies between the planned curriculum by deans and the real clinical learning environment as experienced by students indicate suboptimal learning opportunities for students. Creating powerful workplace-learning experiences and resolving concerns on students use of EMR has to be resolved in a constructive collaboration way between the involved stakeholders, including also EMR designers and hospital administrators. We recommend intense supervision of students’ work in EMR to take full advantage of the technological advances of EMR at the modern clinical site, both for patient care and for medical education.


  • Fe de errores de «Impacto del tratamiento preventivo con agonistas adrenérgicos β2 de acción larga y glucocorticoides inhalados en la morbimortalidad de 1.543 episodios de exacerbación grave de asma»

    by Vicente Plaza, Jesús Bellido-Casado, Gustavo J. Rodrigo, Iván Solarte, Gema Rodríguez-Trigo, Ricardo Sepúlveda, Hugo Neffen, Miguel Perpiñá

    • 21 January 2010
      • Vol. 2010

    Asthma in adults.

    by Rodolfo J Dennis, Ivan Solarte, Gustavo Rodrigo

    About 10% of adults have suffered an attack of asthma, and up to 5% of these have severe disease that responds poorly to treatment. Patients with severe disease have an increased risk of death, but patients with mild-to-moderate disease are also at risk of exacerbations. Most guidelines about the management of asthma follow stepwise protocols. This review does not endorse or follow any particular protocol, but presents the evidence about specific interventions. We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of treatments for chronic asthma? What are the effects of treatments for acute asthma? We searched: Medline, Embase, The Cochrane Library, and other important databases up to June 2008 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). We found 99 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. In this systematic review, we present information relating to the effectiveness and safety of the following interventions. For acute asthma: beta(2) agonists (plus ipratropium bromide, pressured metered-dose inhalers, short-acting continuous nebulised, short-acting intermittent nebulised, and short-acting intravenous); corticosteroids (inhaled); corticosteroids (single oral, combined inhaled, and short courses); education about acute asthma; generalist care; helium-oxygen mixture (heliox); magnesium sulphate (intravenous and adding isotonic nebulised magnesium to inhaled beta(2) agonists); mechanical ventilation; oxygen supplementation (controlled 28% oxygen and controlled 100% oxygen); and specialist care. For chronic asthma: beta(2) agonists (adding long-acting inhaled beta(2) agonists when asthma is poorly controlled by inhaled corticosteroids, or short-acting inhaled beta(2) agonists as needed for symptom relief); inhaled corticosteroids (low dose and increasing dose); leukotriene antagonists (with or without inhaled corticosteroids); and theophylline (when poorly controlled by inhaled corticosteroids).